Pheon Hopes To Stir Up ADC Space With First-In-Class Compound
Launches With $68m Series A
The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.
You may also be interested in...
The Swedish rare disease specialist has expanded its hematology franchise by getting the European rights to ADC Therapeutics’ Zynlonta, which has yet to make much impact commercially in the US.
Following in the wake of Merck & Co's acquisition of VelosBio, the German major is spending big to get hold of the Swiss oncology biotech NBE-Therapeutics which is also targeting the ROR1 protein.
Five months after its lead drug Betalutin failed for follicular lymphoma, Nordic Nanovector has secured its future by teaming up with Trondheim-based APIM and gained access to its mid-stage investigational therapy for ovarian cancer, sarcoma and glioblastoma.